
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Cdx2 CRISPR Activation Plasmid (m) | sc-419618-ACT | 20 µg | $397.00 | |||
Cdx2 CRISPR Activation Plasmid (m2) | sc-419618-ACT-2 | 20 µg | $397.00 |
Cdx2 (caudal type homeobox 2) encodes a homeobox transcription factor that establishes and maintains posterior body patterning during embryogenesis and is a key regulator of trophectoderm specification and intestinal epithelial differentiation in mouse. By binding sequence-specific DNA motifs, CDX2 coordinates transcriptional programs that interface with Wnt/β-catenin signaling, epithelial polarity, and lineage commitment, influencing proliferation and maturation of gut epithelium. Dysregulated CDX2 expression has been associated with altered differentiation states and aberrant epithelial identity, making it a widely used marker and mechanistic node in studies of developmental disorders and gastrointestinal disease biology. In vitro, Cdx2 is frequently leveraged to model fate transitions, organoid maturation, and transcriptional network dynamics in stem and progenitor cell systems.
Cdx2 CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Cdx2 expression without altering the underlying DNA sequence.
Cdx2 CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Cdx2 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Cdx2 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Cdx2 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Cdx2 locus and enabling the study of Cdx2-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Cdx2 pathway restoration in tumor cells with silenced or reduced Cdx2 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.